ClinicalTrials.gg
CompletedNCT01964326Updated Feb 21, 2021Results posted

Actual Use Trial of Atorvastatin Calcium 10 mg

A Phase 3 interventional study of Atorvastatin calcium 10 mg in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,311
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
5th of 75
1,311 · median 148
Started
2013
with 3 others
Phase 3
31 of 77
none open now
Registered
57th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 5th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2013, is one of 31 in phase 3, and was the 57th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • atorvastatin
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age (19 in Alabama).
  • Provide written .
  • Never participated in a study about cholesterol medicines.

Exclusion criteria

Exclusion Criteria:

  • Females subjects who are pregnant or breastfeeding.
  • Subjects with active liver disease.
  • Subjects taking cyclosporine.
  • Subjects with a known allergy to atorvastatin calcium.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Masking
None (open label)
Enrollment
1,311 participants (actual)

Study arms

  • Experimental
    Atorvastatin calcium 10 mg

    Drug: Atorvastatin calcium 10 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants had their LDL-C checked between Weeks 4 and 12. The behavior was considered acceptable if participants had their LDL-C checked between Weeks 2 and 3 (before Week 4) or between Weeks 13 (after Week 12) and 26 or if participants were instructed by a physician that an LDL-C test was not needed.

    Time frame: Day 1 up to Week 26

  2. Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants self-reported an LDL-C level below 130 milligram per deciliter (mg/dL) or normal, or low and decided to continue with atorvastatin OTC or if participants self-reported an LDL-C below 130 mg/dL, or normal, or low but stopped the use because of new conditions preventing them from continuing use. The behavior was considered acceptable if participants self-report LDL-C level between 130 and 135 mg/dL and continued to use atorvastatin OTC without contacting a physician or other health care practitioner or if participants self-reported LDL-C greater than or equal to (\>=) 130 mg/dL('borderline high' or 'high' LDL-C), and contacted a physician after getting the LDL-C test results.

    Time frame: Day 1 up to Week 26

Secondary outcomes

  1. Percentage of Participants Taking an "Ask a Doctor or Pharmacist Before Use" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. 'Ask a doctor or pharmacist before use' medication included human immunodeficiency virus (HIV) medicine, digoxin, telaprevir, rifampin, colchicine, or oral contraceptives. The behavior of the participants was considered correct if participants asked a doctor or pharmacist before use. The behavior was considered acceptable if participants contacted a doctor or pharmacist within 7 days of initiating therapy.

    Time frame: Day 1 up to Week 26

  2. Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled "Stop Use and Ask a Doctor" Symptoms

    Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The "Stop use and ask a doctor" symptoms included: (a) unexplained muscle pain or weakness or tenderness, (b) unusual fatigue, (c) loss of appetite (d) upper belly pain (e) dark-colored urine or (f) yellowing of the whites of eyes or skin. The behavior of the participants was considered correct if participants stopped use and contacted a doctor within 7 days after the event (symptom development).The behavior was considered acceptable if participants either stopped use or contacted a doctor (but did not do both) within the 7 days' timeframe.

    Time frame: Day 1 up to Week 26

07

Results

Posted Jan 27, 2016

Participant flow

Participant flow — Overall Study
MilestoneAtorvastatin
Started1311
Completed1014
Not completed297
Withdrew: Adverse event48
Withdrew: Death2
Withdrew: Protocol violation4
Withdrew: Lost to follow-up88
Withdrew: Withdrawal by subject87
Withdrew: Pregnancy1
Withdrew: No longer meets eligibility criteria1
Withdrew: Physician decision55
Withdrew: Investigator discretion1
Withdrew: Other9
Withdrew: Did not meet eligibility criteria1

Outcome measures

PrimaryPercentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants had their LDL-C checked between Weeks 4 and 12. The behavior was considered acceptable if participants had their LDL-C checked between Weeks 2 and 3 (before Week 4) or between Weeks 13 (after Week 12) and 26 or if participants were instructed by a physician that an LDL-C test was not needed.

Time frame:
Day 1 up to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level
Percentage of participantsAtorvastatin
Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level49.7 (46.6 to 52.7)
PrimaryPercentage of Participants Who Took Appropriate Action Based on Their LDL-C Results

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants self-reported an LDL-C level below 130 milligram per deciliter (mg/dL) or normal, or low and decided to continue with atorvastatin OTC or if participants self-reported an LDL-C below 130 mg/dL, or normal, or low but stopped the use because of new conditions preventing them from continuing use. The behavior was considered acceptable if participants self-report LDL-C level between 130 and 135 mg/dL and continued to use atorvastatin OTC without contacting a physician or other health care practitioner or if participants self-reported LDL-C greater than or equal to (\>=) 130 mg/dL('borderline high' or 'high' LDL-C), and contacted a physician after getting the LDL-C test results.

Time frame:
Day 1 up to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results
Percentage of participantsAtorvastatin
Percentage of Participants Who Took Appropriate Action Based on Their LDL-C Results52.6 (48.4 to 56.8)
SecondaryPercentage of Participants Taking an "Ask a Doctor or Pharmacist Before Use" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. 'Ask a doctor or pharmacist before use' medication included human immunodeficiency virus (HIV) medicine, digoxin, telaprevir, rifampin, colchicine, or oral contraceptives. The behavior of the participants was considered correct if participants asked a doctor or pharmacist before use. The behavior was considered acceptable if participants contacted a doctor or pharmacist within 7 days of initiating therapy.

Time frame:
Day 1 up to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Taking an "Ask a Doctor or Pharmacist Before Use" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication
Percentage of participantsAtorvastatin
Percentage of Participants Taking an "Ask a Doctor or Pharmacist Before Use" Medication Who Followed the Labeling and Contacted a Doctor or Pharmacist Before Using Study Medication29.2 (11.0 to 47.4)
SecondaryPercentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled "Stop Use and Ask a Doctor" Symptoms

Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The "Stop use and ask a doctor" symptoms included: (a) unexplained muscle pain or weakness or tenderness, (b) unusual fatigue, (c) loss of appetite (d) upper belly pain (e) dark-colored urine or (f) yellowing of the whites of eyes or skin. The behavior of the participants was considered correct if participants stopped use and contacted a doctor within 7 days after the event (symptom development).The behavior was considered acceptable if participants either stopped use or contacted a doctor (but did not do both) within the 7 days' timeframe.

Time frame:
Day 1 up to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled "Stop Use and Ask a Doctor" Symptoms
Percentage of participantsAtorvastatin
Percentage of Participants Who Stopped Study Medication Use and Asked a Doctor if They Experienced Any of the Labeled "Stop Use and Ask a Doctor" Symptoms10.2 (4.7 to 15.6)

Adverse events

Collected over Day 1 up to Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin—53/1,234 (4.3%)589/1,234 (47.7%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventAtorvastatin
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/1234
Cerebrovascular accidentNervous system disorders3/1234
AnaemiaBlood and lymphatic system disorders2/1234
DeathGeneral disorders2/1234
CholecystitisHepatobiliary disorders2/1234
BronchitisInfections and infestations2/1234
Ankle fractureInjury, poisoning and procedural complications2/1234
Back painMusculoskeletal and connective tissue disorders2/1234
SyncopeNervous system disorders2/1234
DepressionPsychiatric disorders2/1234
Most frequent other events
Showing 10 of 263
Most frequent other events
EventAtorvastatin
MyalgiaMusculoskeletal and connective tissue disorders53/1234
NasopharyngitisInfections and infestations44/1234
DiarrhoeaGastrointestinal disorders40/1234
HeadacheNervous system disorders37/1234
NauseaGastrointestinal disorders26/1234
ArthralgiaMusculoskeletal and connective tissue disorders26/1234
FatigueGeneral disorders23/1234
Pain in extremityMusculoskeletal and connective tissue disorders20/1234
InfluenzaInfections and infestations19/1234
SinusitisInfections and infestations18/1234

Baseline characteristics

Users/Safety set included all participants reported taking at least 1 dose of study medication or had at least 1 dosing record available or responded 'yes' to the question 'have you started taking Lipitor OTC' in any phone interview, or contacted the study site in any other manner and indicated the use of study product.

Age, Continuous
Age, Continuous(Years)Atorvastatin
Mean57.8 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin
Female593
Male641
08

Study locations

37 sites
  • Robert's Discount Pharmacy
    Hoover, Alabama 35226, United States
  • Pharmacy at the Pig
    McCalla, Alabama 35111, United States
  • Pinson Discount Drugs
    Pinson, Alabama 35126, United States
  • Community Clinical Pharmacy
    Mesa, Arizona 85202, United States
  • Melrose Pharmacy
    Phoenix, Arizona 85013, United States
  • Bi-Rite Quality Pharmacies
    La Habra, California 90631, United States
  • Parkview Compounding Pharmacy
    Rancho Cucamonga, California 91730, United States
  • Garden Drug
    Fort Lauderdale, Florida 33309, United States
  • Pill Box Pharmacy and Medical Supply
    Pembroke Pines, Florida 33026, United States
  • Summerfield Pharmacy
    Riverview, Florida 33569, United States
  • Sutton Family Pharmacy
    Dalton, Georgia 30721, United States
  • Wynn's Pharmacy Inc.
    Griffin, Georgia 30224, United States
  • Catonsville Pharmacy
    Baltimore, Maryland 21228, United States
  • Kemper Drug
    Elk River, Minnesota 55330, United States
  • Goodrich Pharmacy
    Fridley, Minnesota 55432, United States
  • Northfield Pharmacy
    Northfield, Minnesota 55057, United States
  • Cub Pharmacy
    Rosemount, Minnesota 55068, United States
  • Goodrich Pharmacy
    Saint Francis, Minnesota 55070, United States
  • Albers' Medical Pharmacy
    Kansas City, Missouri 64111, United States
  • Countryside Pharmacy
    Savannah, Missouri 64485, United States
  • Texas Road Pharmacy
    Monroe, New Jersey 08831, United States
  • Duran Central Pharmacy
    Albuquerque, New Mexico 87104, United States
  • Sam's Regent Pharmacy
    Albuquerque, New Mexico 87109, United States
  • Family Prescription Center
    Bethlehem, Pennsylvania 18015, United States
  • T.B. Bond Pharmacy
    Hillsboro, Texas 76645, United States
  • Inwood Pharmacy
    Houston, Texas 77070, United States
  • Brick Street Pharmacy
    Tyler, Texas 75701, United States
  • Mountain West Apothecary
    Bountiful, Utah 84010, United States
  • Ridgeview Pharmacy
    Roy, Utah 84067, United States
  • The Apothecary Shoppe
    Salt Lake City, Utah 84102, United States
  • The Medicine Center
    Salt Lake City, Utah 84121, United States
  • Family Plaza Pharmacy
    West Jordan, Utah 84088, United States
  • Montpelier Pharmacy, Inc.
    Montpelier, Virginia 23192, United States
  • Lafayette Pharmacy
    Richmond, Virginia 23221, United States
  • Jim's Pharmacy
    Enumclaw, Washington 98022, United States
  • Ostrom Drugs
    Kenmore, Washington 98028, United States
  • Katterman's Sand Point Professional Pharmacy
    Seattle, Washington 98105, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2013
First posted
Oct 17, 2013
Start
Oct 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Jan 27, 2016
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01964326
Responsible party
Sponsor
First posted
Oct 17, 2013
Start date
Oct 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Jan 27, 2016
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion